APDN — Trading on Nasdaq with Adjusted Shares Begins

Common Stock Trading Begins on NASDAQ - Split-Adjusted

Lyell Immunopharma, Inc.'s common stock will begin trading on a split-adjusted basis on the NASDAQ effective June 2, 2025. This follows a reverse stock split authorized by shareholders at the May 15, 2025 annual meeting, converting every 20 shares into one share. The split is designed to enhance the stock's marketability after reducing the number of outstanding shares from approximately 296 million to about 14.8 million. The new CUSIP number for the shares post-split will be 55083R203. No fractional shares will be issued; cash payments will be made for any resulting fractions, but the overall percentage ownership for stockholders remains unaffected.

Admit Shares to Trading on Nasdaq First North

Admicom Oyj announced the admission of its shares to trading on the Nasdaq First North Growth Market Finland, scheduled for June 10, 2025. This event follows a share exchange agreement signed on June 5, 2025, through which Admicom acquired 13.7% of its subsidiary Aitio Finland Oy, bringing its total ownership to 100%. The acquisition was executed for approximately EUR 600,000, with a strategic focus on integrating minority shareholders into the development of the Group's product portfolio. The directed share issue accompanying this event will increase Admicom’s share capital by approximately 0.2%. Aitio Finland provides significant contributions to Admicom's operations in the digitalisation of the construction industry, enhancing its service offerings to clients. The financial impact of this acquisition is not expected to be material to Admicom's future prospects.

• investors.admicom.fi/releases-and-reports/

Trading on The Nasdaq after Reverse Stock Split

ClearOne, Inc. will implement a 1-for-15 reverse stock split effective June 2, 2025, at 5:00 p.m. ET, subject to shareholder approval on May 30. The company's common stock will begin trading on a reverse stock split adjusted basis on The Nasdaq Capital Market at market open on June 3, 2025. This strategic move aims to increase the share price to comply with Nasdaq's minimum bid price requirement, reducing the number of outstanding shares from approximately 26 million to about 1.7 million. The company's ticker symbol "CLRO" will remain unchanged, though shares will be assigned a new CUSIP number: 18506U203.

Common Stock Begins Trading on Split-Adjusted Basis

On June 9, 2025, Bolt Biotherapeutics will begin trading its common stock on Nasdaq on a split-adjusted basis following a one-for-twenty reverse stock split approved by the Board of Directors on May 27, 2025. At the effective time of the split, every 20 shares will convert into one share, with adjustments to stock options and equity plans accordingly. The common stock will retain its ticker symbol "BOLT" and its par value will remain at $0.00001. This move is part of the company's efforts to adjust its capital structure ahead of further corporate activities.